Catheter Precision, Inc. (VTAK) - Dilution Analysis

10-Q filing | 2.7M shares outstanding

8-K filing: Catheter Precision, Inc. issued Series C-2 and Series D Convertible Preferred Stock for aggregate gross proceeds and acquisition consideration. ($3.47M proceeds)

10-K filing | 1.7M shares outstanding

8-K filing: Catheter Precision, Inc. entered into a securities purchase agreement for the issuance and sale of Series C-1, C-2, and C-3 Convertible Preferred Stock, and also agreed to acquire FLYTE shares and Ponderosa Air membership interests from Creatd, Inc. ($5.56M proceeds)

10-Q filing | 1.6M shares outstanding

8-K filing: Stock split 1-for-19 | Outstanding: 18,861,579 → 1,227,764

10-Q filing | 18.9M shares outstanding

8-K filing: On June 5, 2025, Catheter Precision, Inc. approved the issuance of a placement agent common stock purchase warrant to Ladenburg Thalmann & Co., Inc. to acquire 257,143 shares at $0.5424 per share.

8-K filing: The company is selling 4,333,333 shares of common stock in an at-the-market offering at an assumed price of $0.30 per share, resulting in estimated net proceeds of $1.2 million and a pro forma adjusted net tangible book value of $(0.95) per share. ($1.3M proceeds)

S-3 filing: This S-3 filing covers the offer and resale of up to 12,859,716 shares of common stock by the Selling Stockholders.

10-Q filing | 9.3M shares outstanding

8-K filing: Catheter Precision, Inc. entered into a Securities Purchase Agreement to sell Series B Convertible Preferred Stock and issue Series L warrants. ($3.0M proceeds)

8-K filing: Catheter Precision, Inc., through its subsidiary Cardionomix, Inc., acquired assets related to the Cardiac Pulmonary Nerve Simulation (CNPS) System from Cardionomic (assignment for the benefit of creditors), LLC on May 5, 2025.

8-K filing: Catheter Precision, Inc. formed its subsidiary Cardionomix, Inc. and entered into an asset purchase agreement with Cardionomic (assignment for the benefit of creditors), LLC to purchase assets related to Assignor's late-stage treatment in development for acute decompensated heart failure.

8-K filing: Catheter Precision, Inc. is in negotiations through its subsidiary Cardionomix, Inc. to acquire assets from Cardionomic (assignment for the benefit of creditors), LLC, in exchange for 1,000,000 shares of the Company's common stock and a $1.5 million promissory note.

10-K filing | 8.0M shares outstanding

S-3 filing: The company intends to offer and sell common stock and preferred stock up to an aggregate amount of $20,000,000.

S-1 filing: This S-1 filing covers the offer and resale of up to 10,695,962 shares of common stock by selling stockholders, underlying Series K Common Stock Purchase Warrants issued as part of a warrant repricing.

10-Q filing | 3.5M shares outstanding

8-K filing: Catheter Precision, Inc. entered into a waiver agreement with the Jenkins Family Charitable Institute, allowing the Institute to exercise pre-funded warrants to acquire 235,000 shares of Company common stock for $23.50. ($0.0M proceeds)

8-K filing: Catheter Precision repriced certain warrants and entered into inducement letters with investors to exercise existing warrants, potentially resulting in the issuance of approximately 5.3 million shares of common stock and approximately $3.7 million in gross proceeds. ($4.89M proceeds)

8-K filing: Catheter Precision, Inc. completed a public offering on September 3, 2024, issuing common stock units and pre-funded units, resulting in gross proceeds of approximately $3.6 million. ($0.0M proceeds)

S-1/A filing: This is a firm commitment public offering of up to 1,357,466 common stock units of Catheter Precision, Inc., each consisting of: (i) one share of our voting common stock, (ii) a Series H warrant to purchase one share of our common stock (the "Series H Warrant"), (iii) a Series I Warrant to purchase one share of our common stock (the "Series I Warrant"), and (iv) a Series J warrant to purchase one share of our common stock (the "Series J Warrant").

10-Q filing | 0.8M shares outstanding

8-K filing: Stock split 1-for-10 | Outstanding: 8,387,631 → 901,251

8-K filing: The Company issued 814,228 shares of common stock upon conversion of Series A Preferred Stock and intends to effect a 1-for-10 reverse stock split on July 15, 2024, reducing the number of issued shares from 8,387,631 to approximately 838,763.

S-1/A filing: This is an S-1/A filing related to a proposed offering of securities, covering expenses, use of proceeds, and other offering-related activities.

S-1/A filing: This S-1/A filing details a firm commitment public offering of common stock and pre-funded warrants, along with underwriter warrants, to support operations, clinical trials, working capital, and general corporate purposes.

S-1 filing: S-1 filing for a firm commitment public offering of common stock and warrants.

10-Q filing | 7.6M shares outstanding

10-K filing | 7.0M shares outstanding

8-K filing: Catheter Precision, Inc. issued 546,776 shares of its common stock in connection with the conversion of 875 shares of its outstanding Series A Convertible Preferred Stock on January 24, 2024.

POS AM filing: This prospectus covers the offer and resale of up to 331,608 shares of common stock by the Selling Stockholders.

POS AM filing: This prospectus covers the offer and resale from time to time of up to 13,148,186 shares of common stock by the Selling Stockholders.

10-Q filing | 7.0M shares outstanding

10-Q filing | 5.4M shares outstanding

8-K filing: Ra Medical Systems, Inc. issued 546,776 shares of its common stock in connection with the conversion of 875 shares of its outstanding Series A Convertible Preferred Stock on July 24, 2023.

8-K filing: Ra Medical Systems, Inc. issued 1,093,552 shares of its common stock in connection with the conversion of 1,750 shares of its outstanding Series A Convertible Preferred Stock on July 5, 2023.

10-Q filing | 2.2M shares outstanding

S-3 filing: This is an S-3 filing for the offer and resale of up to 14,023,539 shares of common stock by selling stockholders.

S-3 filing: This S-3 filing covers the offer and resale from time to time of up to 14,997,154 shares of common stock by the Selling Stockholders.

10-K filing | 5.0M shares outstanding

S-3 filing: This S-3 filing registers the offer and resale of up to 331,608 shares of common stock by selling stockholders, underlying Series E Common Stock Purchase Warrants.

8-K filing: Ra Medical Systems, Inc. completed its acquisition of Catheter Precision, Inc. and entered into a private placement with Armistice, while also repricing certain existing warrants. ($1.3M proceeds)

10-Q filing | 2.2M shares outstanding

8-K filing: Stock split 1-for-50 | Outstanding: 54,514,828 → 1,090,296

S-3 filing: This S-3 filing relates to the offer and resale of up to 22,202,503 shares of common stock underlying Series C Common Stock Purchase Warrants issued to selling stockholders as part of a warrant repricing.

10-Q filing | 54.5M shares outstanding

8-K filing: Ra Medical Systems, Inc. repriced existing warrants from $0.50 to $0.28 and entered into warrant inducement offer letters with certain investors to immediately exercise up to 2.2 million of the existing warrants, expecting to receive aggregate gross proceeds of approximately $6.2 million from the exercise of the Series A Warrants resulting in the issuance of up to an aggregate of approximately 22.2 million shares of common stock and a pro forma shares of common stock outstanding of approximately 54.52 million after giving effect to the exercise of the Series A Warrants. ($6.2M proceeds)

POS AM filing: This prospectus relates to the offering of 9,535,000 units of Ra Medical Systems, Inc., each unit consisting of one share of common stock, one warrant to purchase one share of our common stock at an exercise price of $0.50 per share which will be immediately exercisable and will expire one year from the date of issuance, or a Series A Warrant, and one warrant to purchase one share of our common stock at an exercise price of $0.50 per share which will be immediately exercisable and will expire seven years from the date of issuance, or a Series B Warrant.

10-Q filing | 32.3M shares outstanding

10-K filing | 31.5M shares outstanding

8-K filing: Ra Medical Systems, Inc. completed a public offering of units consisting of common stock, pre-funded warrants, Series A warrants, and Series B warrants, resulting in net proceeds of approximately $11.0 million.

S-1/A filing: This S-1/A filing describes the terms of the company's capital stock, Series A Warrants, Series B Warrants, and pre-funded warrants included in the offering, as well as registering shares of common stock included in units and issuable upon exercise of warrants.

S-1/A filing: This is an S-1/A filing for units, pre-funded units, and shares of common stock issuable upon exercise of the warrants included in the units and pre-funded units.

S-1/A filing: This S-1/A filing describes the terms of the company's common stock, preferred stock, warrants and pre-funded warrants included in this offering.

S-1 filing: Ra Medical Systems, Inc. is offering units, each consisting of one share of common stock and one warrant to purchase one share of common stock, and pre-funded units, each consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock.

10-Q filing | 7.0M shares outstanding

10-Q filing | 7.0M shares outstanding

10-Q filing | 3.3M shares outstanding

10-K filing | 3.3M shares outstanding

S-3 filing: Ra Medical Systems, Inc. is offering common stock, preferred stock, debt securities, warrants, subscription rights and units up to an aggregate offering price of $50 million.

8-K filing: Stock split 1-for-25 | Outstanding: 72,468,337 → 2

10-Q filing | 72.5M shares outstanding

8-K filing: Ra Medical Systems, Inc. completed a public offering of 31,188,100 units at $0.35 per unit and 3,097,614 pre-funded units at $0.3499 per pre-funded unit, with net proceeds of approximately $10.6 million. ($10.84M proceeds)

S-1/A filing: This S-1/A filing registers units consisting of common stock and warrants, and pre-funded units consisting of pre-funded warrants and warrants, along with associated shares, and placement agent warrants.

8-K filing: Ra Medical Systems, Inc. completed a public offering of 20,725,190 units, each consisting of one share of common stock and one warrant, and 1,497,032 pre-funded units, each consisting of one pre-funded warrant and one warrant, for net proceeds of approximately $8.7 million. ($9.33M proceeds)

S-1/A filing: This S-1/A filing includes exhibits related to engagement letter with H.C. Wainwright & Co., Amended and Restated Certificate of Incorporation and Bylaws, specimen common stock certificate, description of capital stock, warrants, securities purchase agreement, and other agreements.

S-1/A filing: Ra Medical Systems, Inc. is offering up to 11,779,950 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock, and up to 11,779,950 pre-funded units, each pre-funded unit consisting of one pre-funded warrant to purchase one share of common stock and one warrant to purchase one share of common stock.

10-Q filing | 13.9M shares outstanding

S-1 filing: S-1 filing for common stock, pre-funded warrants, and shares of common stock issuable upon exercise of the pre-funded warrants with a proposed maximum aggregate offering price of $12,000,000.

10-K filing | 13.8M shares outstanding